Posttraumatic midazolam administration does not influence brain damage after experimental traumatic brain injury.

ABSTRACT:

Background

The benzodiazepine midazolam is a γ-aminobutyric acid (GABA)-A receptor agonist frequently used for sedation or stress control in patients suffering from traumatic brain injury (TBI). However, experimental studies on benzodiazepines have reported divergent results, raising concerns about its widespread use in patients. Some studies indicate that benzodiazepine-mediated potentiation of GABAergic neurotransmission is detrimental in brain-injured animals. However, other experimental investigations demonstrate neuroprotective effects, especially in pretreatment paradigms. This study investigated whether single-bolus midazolam administration influences secondary brain damage post-TBI.

Methods

Two different midazolam dosages (0.5 and 5 mg/kg BW), a combination of midazo

SUBMITTER: Sebastiani A 

PROVIDER: S-EPMC8896377 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature